EC Number   |
Inhibitors |
Structure |
|---|
    2.7.1.1 | (1R)-6-bromo-3-ethenyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol |
weak activity on hexokinase, 51% growth inhibition on asexual stage Plasmodium falciparum parasite |
   |
| 2.7.1.1 | (2-pyridin-4-ylethane-1,1-diyl)bis(phosphonic acid) |
mixed to non-competitive inhibitors against ATP, non-competitive against D-glucose |
|
| 2.7.1.1 | (22E,24R)-6beta-methoxyergosta-7,9(11),22-triene-3beta,5alpha-diol |
steroid from Ganoderma sinense. Potential drug candidate targeting at hexokinase 2 for cancer therapy |
|
| 2.7.1.1 | (3-bromo-phenyl)-aminomethylene-1,1-bisphosphonate |
- |
|
| 2.7.1.1 | (9-ethyl-9H-3-carbazolyl)-aminomethylene-1,1-bisphosphonate |
- |
|
| 2.7.1.1 | 1,10-phenanthroline |
20 mM, 96% inhibition |
|
| 2.7.1.1 | 1,5-Anhydro-D-glucitol 6-phosphate |
HK I and HK I+, the D84A mutant of HK I has 2fold increased Ki, HK I: low millimolar concentrations of phosphate antagonize inhibition by competing for an anion binding site in the N-terminal half of HK I, HK I+: insert abolishes the antagonism of phosphate |
|
| 2.7.1.1 | 1,5-Anhydro-D-glucitol 6-phosphate |
intact enzyme and catalytically active 51 kDa C fragment of hexokinase |
|
| 2.7.1.1 | 1,5-Anhydro-D-glucitol 6-phosphate |
less effective than glucose 6-phosphate, competitive versus ATP |
|
| 2.7.1.1 | 1,5-Anhydro-D-glucitol 6-phosphate |
wild-type and nonaggregating interface mutant hexokinase I, inhibition is relieved by phosphate |
|
